Register
EMA grants marketing authorization to Myalepta for leptin deficiency |
Journal Updates
eMediNexus Coverage from: 
EMA grants marketing authorization to Myalepta for leptin deficiency
eMediNexus,  12 June 2018
remove_red_eye 530 Views
#Diabetes and Endocrinology #Pharmacist

0 Read Comments                

The European Medicines Agency (EMA)s Committee for Medicinal Products for Human Use (CHMP) has recommended granting of marketing authorization for Myalepta indicated for the treatment of complications of leptin deficiency in patients with generalized or partial lipodystrophy which is often associated with severe metabolic abnormalities, including hypertriglyceridemia, insulin resistance and/or diabetes. Myalepta, which is a recombinant human leptin analog, will be available as an 11.3 mg powder for solution for injection.


Comments

Comments on eMediNexus are moderated. We retain the right to remove any comments at our sole discretion.